We return briefly to a fundamental topic which we have written about before – in both 2019 and 2020: If THC is not permitted in products, to what level of precision is the product to be examined to establish the THC level?
Please wait, loading...
We return briefly to a fundamental topic which we have written about before – in both 2019 and 2020: If THC is not permitted in products, to what level of precision is the product to be examined to establish the THC level?
Europe’s hemp industry hit a milestone last week when the European Union’s top court liberated CBD from the jurisdiction of an international drug treaty, declaring that hemp-derived cannabidiol is not a narcotic.
In May we published an analysis of the Judgement of Advocate General Tanchev in respect of the Kanavape case, “Can the movement of CBD within the European Member States be prohibited it if is derived from prohibited elements of the plant?”. We observed that there was “good” and “bad” in the provisional Opinion.
In this video Stephen Oliver, Co-Founder of The Canna Consultants, explains the opportunities and barriers to investment in the European Space during the Med-Cann Virtual Summit. He offers some great advice, addressing the need to think alternatively and adapt to new situations.
The FSA refutes claims made by a prominent self-styled trade organisation that it has changed its toxicology policy.
SAFETY STANDARDS SHOULD BE DRIVEN BY THE REGULATORS AND SCIENCE, NOT BY COMMERCIAL ENTITIES OR ASSOCIATIONS. YOU MAY CHOOSE YOUR OWN PATH, BUT TO DISMISS OUR ANALYSIS MAY BE UNWISE.
Stephen Oliver former Customs Investigator and Matt Lawson Barrister are both experts in the cannabinoid industry, they are the founders of The Canna Consultants and will be speaking at the event on both days.
Stephen Oliver and Matt Lawson are both experts in the cannabinoid industry, they are the founders of The Canna Consultants and will be speaking at the Cannabis Investment Summit World (CISW) which takes place 11-13 of November 2020.
We have reproduced the questions as they have been submitted in order not to interfere with them. If you are unable to answer the question as drafted, we would encourage you to answer what you feel is the import of the question in order that market participant is not disadvantaged by potentially poor language selection in their phraseology.
Is the FSA's policy that any CBD "New to Market" products will be treated differently than those "Already on the Market" justified despite there being no difference in their potential risks? Perhaps the more telling question is whether the policy will be sustained in the face of an inevitable legal challenge?